Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer

Article

Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.

Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.

Recent Videos
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
A radiation oncologist discussed the theranostics treatment landscape and career opportunities in the field at the 2025 ACRO Summit.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content
FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

Ariana Pelosci
March 28th 2025
Article

Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
March 24th 2025
Podcast

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

ASTCT Women’s History Month Spotlight: Sung-Yun Pai, MD

ASTCT Women’s History Month Spotlight: Sung-Yun Pai, MD

American Society for Transplantation and Cellular Therapy
March 28th 2025
Article

In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Omitting Breast Surgery Stalls Cancer Recurrence in Exceptional Responders

Omitting Breast Surgery Stalls Cancer Recurrence in Exceptional Responders

Ariana Pelosci
March 28th 2025
Article

At 5 years, 100% of patients with breast cancer who did not receive surgery had ipsilateral breast tumor relapse-free survival.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.